Ian Cooper

Ian Cooper

InvestorPlace Contributor

Ian Cooper has helped traders grow and protect their wealth since 1999.

Over the last 24 years, he’s taught thousands of investors how to trade news flow and herd mentality using a unique blend of technical and fundamental analysis. In fact, Cooper created the ADD News Flow Strategy, which allows us to trade the anticipation, dissemination, and the death of news flow by exploiting herd mentality.

Cooper was among the few analysts to spot the financial crisis of 2008, the top of subprime and Alt-A, the death of Lehman Brothers, Bear Stearns, and New Century Financial, and even the Dow’s collapse to 6,500, as well as its recovery. He even called for gold to rally well above $1.500 when it traded under $600.

At the moment, Cooper makes use of technical, fundamental and news analysis, to help individual investors grow their wealth. He’s a firm believer that hard work and thorough research will lead to investment success.

Recent Articles

The Top 3 Ways to Trade On Coronavirus Volatility

By Ian Cooper, InvestorPlace Contributor

Here are the best ways for bearish investors to hedge their portfolios against the market dip on coronavirus as volatility runs higher.

Google Stock Is a Top Blood-in-the-Street Opportunity

By Ian Cooper, InvestorPlace Contributor

Once the smoke clears from the coronavirus story, I strongly believe Google stock will refill its bearish gap at $1,532.

3 Top Stocks You Should Watch to Invest Like Berkshire Hathaway

By Ian Cooper, InvestorPlace Contributor

One of the best ways to profit is to invest like Warren Buffett. Here are three Berkshire Hathaway stocks that he's watching now.

Adobe Stock Could Hit $450 in 2020 for These Reasons

By Ian Cooper, InvestorPlace Contributor

Adobe is a long-term winner. And given high demand for its products and large earnings growth, ADBE stock of one of the best to own for 2020.

First-Mover Advantage Will Benefit Amarin Stock More Than You Think

By Ian Cooper, InvestorPlace Contributor

There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.

Load More